GVBL

The stock has been placed in Additional Surveillance Measure (ASM) list LTASM - I.

The stock has been placed in Graded Surveillance Measure (GSM) list GSM - 0.

Genomic Valley Biotech Ltd.

BSE: 539206

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Biotechnology

30.39+1.4 (+4.79%)

8 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

Score not available

Value Score

Score not available

Price Momentum Score

Score not available

QVM Score

Score not available

Key Metrics

Market Cap

9.28

P/E (TTM)

306.41

P/B

2.36

P/S (TTM)

34.71

EV/EBITDA

211.61

CAPE (5Y)

44.60

ROE (TTM)

0.77

ROCE (TTM)

1.02

ROA (TTM)

0.70

Avg 3Y ROE

3.59

Earnings 3Y CAGR

-63.88

Sales 3Y CAGR

-53.86

Sales 5Y CAGR

5.15

Debt/Equity

0.00

Consensus TP

Strong Buy %

Promoter Holding

46.06

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Genomic Valley Biotech Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.0 as on 31 Mar 2026 and Debt to Equity remained same in the last 1 year

What is Debt to Equity?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 306.41 indicates that the stock is expensive on a standalone basis and is at a 370.1% premium to industry median P/E

What is P/E Ratio?

Median: 65.18

Value 306.41

21.15306.41

Low and declining ROE

The company reported low ROE of 0.77% for 12-month ended 31 Mar 2026 and ROE declined by -880 bps from 1 year ago

What is ROE (FY)?

Moderate operating margin but declining trend

The company reported moderate operating margin of 14.97% for 12-month ended 31 Mar 2026 but operating margin declined by -3681 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of -68.3% for 12-month ended 31 Mar 2026 and the growth was 82.57 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 14.27

Value -68.3

-78.3517.09

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -91.42% for 12-month ended 31 Mar 2026 and the growth was 60.11 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Not enough talking points with neutral stance

Financial Snapshot

See detailed analysis

Multi-year trends for Genomic Valley Biotech Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Genomic Valley Biotech Ltd. Shareholding Pattern

Quarterly breakdown of Genomic Valley Biotech Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.18	67.18	66.32	65.04	64.20	64.14	54.67	46.83	46.78	46.72	46.72	46.06	46.06
Indian Promoter	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.85	67.18	67.18	66.32	65.04	64.20	64.14	54.67	46.83	46.78	46.72	46.72	46.06	46.06
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	32.15	32.15	32.15	32.15	32.15	32.15	32.15	32.15	32.15	32.15	32.15	32.15	32.82	32.82	33.68	34.96	35.80	35.86	45.33	53.17	53.22	53.28	53.28	53.94	53.94
Bodies Corporate	-	-	-	-	-	-	-	-	-	-	-	-	0.65	0.65	0.94	0.88	0.03	0.03	0.03	0.01	0.01	0.01	0.02	0.01	1.26
Others (incl. Retail) No. of shareholders	32.15 361	32.15 363	32.15 366	32.15 367	32.15 368	32.15 368	32.15 368	32.15 368	32.15 368	32.15 372	32.15 372	32.15 374	32.17 376	32.17 377	32.74 586	34.08 1,009	35.77 1,328	35.83 1,535	45.30 2,123	53.16 2,494	53.21 2,501	53.27 2,457	53.26 2,455	53.93 2,519	52.68 2,478

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

Genomic Valley Biotech Ltd. is not part of any tracked index.

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Genomic Valley Biotech Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
YOGESH AGRAWAL Promoter	December-2024	Market Sale (Disposal) 12th Dec 2024	47.17 %	₹ 95.42	13.61 k	₹ 12.98 lac
YOGESH AGRAWAL Promoter	December-2024	Market Sale (Disposal) 12th Dec 2024	47.17 %	₹ 95.42	13.61 k	₹ 12.98 lac
Yogesh Agrawal Promoter	November-2024	Market Sale (Disposal) 7th Nov 2024	47.86 %	₹ 99.56	21.04 k	₹ 20.94 lac
PARUL AGRAWAL Director	October-2024	Market Sale (Disposal) 18th Oct 2024	0.72 %	₹ 94.44	22.00 k	₹ 20.78 lac
PARUL AGRAWAL Director	October-2024	Market Sale (Disposal) 17th Oct 2024	3.91 %	₹ 91.03	97.40 k	₹ 88.66 lac
PARUL AGRAWAL Director	September-2024	Market Sale (Disposal) 26th Sep 2024	4.50 %	₹ 80.84	18.05 k	₹ 14.59 lac
PARUL AGRAWAL Director	September-2024	Market Sale (Disposal) 19th Sep 2024	5.01 %	₹ 76.01	15.55 k	₹ 11.82 lac
YOGESH AGRAWAL Director	September-2024	Market Sale (Disposal) 13th Sep 2024	51.60 %	₹ 73.28	15.34 k	₹ 11.24 lac
YOGESH AGRAWAL Director	September-2024	Market Sale (Disposal) 9th Sep 2024	52.10 %	₹ 71.23	14.66 k	₹ 10.44 lac
PARUL AGRAWAL Director	September-2024	Market Sale (Disposal) 6th Sep 2024	5.80 %	₹ 67.45	16.60 k	₹ 11.19 lac

No corporate action data available.

Company Profile

Overview of Genomic Valley Biotech Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Genomic Valley Biotech Limited is an India-based company, which is engaged in the business of consultancy, and trading in agricultural and horticultural products. The Company is providing consultancy on high-tech cultivation through environment-controlled poly houses, NFT & DFT and others, and organ...

Key personnel

Mrs. Aditya Aditya

Company Secretary, Compliance Officer

Mr. Yogesh Kumar AgrawalD

Executive Chairman of the Board, Managing Director, Chief Financial Officer

Mrs. Parul AgrawalD

Non-Executive Non Independent Director

Mrs. Jyoti BansalD

Additional Non-Executive Independent Director

Mr. Yogainder Kumar GuptaD

Non-Executive Independent Director

Mr. Praveen Kumar MishraD

Additional Non-Executive Independent Director

Incorporated on

15 Mar 1996

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

10 Jul 2015

Free Float

7,66,793

Website

https://www.genomicvalley.com/

Phone no.

+918506986526

Address

4 K.M. Stone, Berry Charra Road, P.O. Tanda Hari, Teh. Bahadurgarh, Dist. Jhajjar, BAHADURGARH, 124507, India

Frequently Asked Questions

What is the current share price of Genomic Valley Biotech Ltd.?

The current share price of Genomic Valley Biotech Ltd. is ₹ 30.39 as of 8 Jul 2026.

What is the market capitalisation of Genomic Valley Biotech Ltd.?

The market capitalisation of Genomic Valley Biotech Ltd. stands at ₹ 9.28 Cr.

What is the PE ratio of Genomic Valley Biotech Ltd.?

The Price-to-Earnings (PE) ratio of Genomic Valley Biotech Ltd. is 306.41 as of the latest trailing twelve months data.

What is the ROE and ROCE of Genomic Valley Biotech Ltd.?

Genomic Valley Biotech Ltd. has a Return on Equity (ROE) of 0.77% and a Return on Capital Employed (ROCE) of 1.02% as per the latest financial reports.

What is the 52-week high and low of Genomic Valley Biotech Ltd.?

The 52-week high of Genomic Valley Biotech Ltd. is - and the 52-week low is -.

What is the dividend yield of Genomic Valley Biotech Ltd.?

The dividend yield of Genomic Valley Biotech Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Genomic Valley Biotech Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 52.68% of Genomic Valley Biotech Ltd. shares.

What sector does Genomic Valley Biotech Ltd. belong to?

Genomic Valley Biotech Ltd. operates in the Healthcare sector.

What is the beta of Genomic Valley Biotech Ltd.?

The beta of Genomic Valley Biotech Ltd. is 0.48, indicating its price volatility relative to the broader market. Over the past 1 year, Genomic Valley Biotech Ltd. has delivered an absolute return of -35.89%.

What is the RSI of Genomic Valley Biotech Ltd.?

The 14-day Relative Strength Index (RSI) of Genomic Valley Biotech Ltd. is 52.79, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Genomic Valley Biotech Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Genomic Valley Biotech Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile

Holdings and Presence